CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $4.12B, above the global median of $1.15B
- PositionReturn on equity is 38%, higher than 95% of its Biotechnology peers (median -22.2%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
27.46BCNY4.12B · vs all stocks (USD)
Trailing P/E
49.26xvs Biotechnology peers
Revenue (TTM)
1.64BCNY245.82M · vs all stocks (USD)
Profit Margin
33.52%vs Biotechnology peers
Beta
-0.1130xvs all stocks
52-Week Change
1.71%vs all stocks
Forward Annual Dividend Yield
0.00%vs all stocks
Market Capitalization
27.46BCNY4.12B · vs all stocks (USD)
Enterprise Value
24.68BCNY3.70B · vs all stocks (USD)
Trailing P/E
49.26xvs Biotechnology peers
Forward P/E
79.60xvs Biotechnology peers
Price to Sales (TTM)
16.06xvs Biotechnology peers
Price to Book (MRQ)
15.31xvs Biotechnology peers
Enterprise to Revenue
15.05xvs Biotechnology peers
Enterprise to EBITDA
49.73xvs Biotechnology peers
Gross Margin
87.48%vs Biotechnology peers
Profit Margin
33.52%vs Biotechnology peers
Operating Margin
-6.54%vs Biotechnology peers
Return on Assets (TTM)
8.80%vs Biotechnology peers
Return on Equity (TTM)
38.00%vs Biotechnology peers
Revenue (TTM)
1.64BCNY245.82M · vs all stocks (USD)
Revenue per Share (TTM)
6.19CNYUpdated Oct 24, 2026Quarterly Revenue Growth
44.20%vs Biotechnology peers
Gross Profit (TTM)
1.53BCNY229.38M · vs all stocks (USD)
EBITDA (TTM)
496.32MCNY74.38M · vs all stocks (USD)
Net Income (TTM)
549.87MCNY82.41M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
78.95%vs Biotechnology peers
Operating Cash Flow (TTM)
796.75MCNY119.41M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
191.14MCNY28.65M · vs all stocks (USD)
Forward Annual Dividend Yield
0.00%vs all stocks
Trailing Annual Dividend Rate
0.00CNYUpdated Oct 24, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
810.48MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
77.63MCNYFY2025 · Dec 31, 2025Gross Profit
732.85MCNYFY2025 · Dec 31, 2025Operating Income
-195.38MCNY-29.28M · vs all stocks (USD)
Pre-tax Income
-168.65MCNYFY2025 · Dec 31, 2025Income Tax Expense
-3.53MCNYFY2025 · Dec 31, 2025Net Income
-165.13MCNYFY2025 · Dec 31, 2025EBIT
-144.45MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-91.84MCNYFY2025 · Dec 31, 2025Research & Development
429.91MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
337.73MCNYFY2025 · Dec 31, 2025Other Operating Expenses
9.39MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
55.12MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
24.20MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.6200CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.6200CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
262.82MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
262.82MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-165.13MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
2.18MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-207.92MCNYFY2025 · Dec 31, 2025Free Cash Flow
-389.39MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
124.66MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-165.13MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-24.00MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-24.40MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
5.60MCNYFY2025 · Dec 31, 2025Capital Expenditures
-181.47MCNYFY2025 · Dec 31, 2025Sale of Investments
125.83MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-55.63MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.13BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.01BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-26.09MCNYFY2025 · Dec 31, 2025Other Financing Charges
-98.39MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-7.50MCNYFY2025 · Dec 31, 2025Shares Outstanding
264.71MSharesUpdated Oct 24, 2026Float Shares
167.29MSharesUpdated Oct 24, 2026% Held by Insiders
28.20%vs all stocks
% Held by Institutions
29.08%vs all stocks
Total Cash (MRQ)
2.47BCNY370.14M · vs all stocks (USD)
Total Cash per Share (MRQ)
9.33CNYUpdated Oct 24, 2026Total Debt (MRQ)
812.94MCNY121.83M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4725xvs Biotechnology peers
Current Ratio (MRQ)
2.50xvs Biotechnology peers
Book Value per Share (MRQ)
6.50CNYUpdated Oct 24, 2026Total Assets
2.97BCNY444.99M · vs all stocks (USD)
Total Current Assets
2.44BCNYFY2025 · Dec 31, 2025Total Liabilities
1.89BCNYFY2025 · Dec 31, 2025Total Non-current Assets
526.08MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
460.80MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.43BCNYFY2025 · Dec 31, 2025Cash
1.91BCNYFY2025 · Dec 31, 2025Cash Equivalents
124.52MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.03BCNYFY2025 · Dec 31, 2025Accounts Receivable
151.22MCNYFY2025 · Dec 31, 2025Inventory
173.27MCNYFY2025 · Dec 31, 2025Accounts Payable
244.16MCNYFY2025 · Dec 31, 2025Short-term Debt
1.04BCNYFY2025 · Dec 31, 2025Other Current Liabilities
408.91KCNYFY2025 · Dec 31, 2025Long-term Debt
92.60MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
358.49MCNYFY2025 · Dec 31, 2025Common Stock (Book)
264.71MCNYFY2025 · Dec 31, 2025Retained Earnings
-2.28BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.08BCNY161.93M · vs all stocks (USD)
52-Week Low
75.10CNYUpdated Oct 24, 202652-Week High
160.00CNYUpdated Oct 24, 202652-Week Change
1.71%vs all stocks
Beta
-0.1130xvs all stocks
50-Day MA
112.11CNYUpdated Oct 24, 2026200-Day MA
104.32CNYUpdated Oct 24, 2026Avg 10-Day Volume
2.56MSharesUpdated Oct 24, 2026Avg 30-Day Volume
3.32MSharesUpdated Oct 24, 2026Diluted EPS (TTM)
2.02CNYUpdated Oct 24, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 38%, higher than 95% of its Biotechnology peers (median -22.2%)Significant
Return on equity: 0.38Industry median: -0.22Industry P95: 0.23Peers compared: 184
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.66
Altman Z-Score 8.17: safe zoneNotable
Altman Z-Score: 8.17
High structural barrier to entryNotable
Barrier to Entry: 0.71
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $4.12B, above the global median of $1.15BNotable
Market cap (USD): 4,115,950,892.891Global Median: 1,150,342,212.262
Levered free cash flow is $28.65M, above the global median of $18.98MNotable
Levered free cash flow (USD): 28,646,899.951Global Median: 18,979,762.15
Companies that share the same coordination system — how they create, deliver, or capture value.
AbCellera Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Viking Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
China Medical System Holdings Limited
Tier 1ProductionApproval-Gated PipelineRule
J.B. Chemicals & Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Xuanzhu Biopharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Changchun High-Tech Industry Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Apeloa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tango Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
Tier 1ProductionApproval-Gated PipelineRule
LivaNova PLC
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Alnylam Pharmaceuticals Inc.
2 interpretationsIndustry-Benchmarked ROA and Margin ElevatedRevenue Growing With Receivables Growing
Castech Inc.
2 interpretationsIndustry-Benchmarked ROA and Margin ElevatedRevenue Growing With Receivables Growing
Motorola Solutions, Inc.
2 interpretationsIndustry-Benchmarked ROA and Margin ElevatedRevenue Growing With Receivables Growing